MediShield Life coverage is increasing. Do you still need a Shield plan?

MediShield Life claim limits and premiums will both change progressively from April 2025 onwards. Benefit and premium changes are as recommended by the MediShield Life council and have been accepted by the government. Here is all you need to know about the changes.

iFAST Insurance Team
iFAST Insurance Team22 Oct 2024 6284 Views


Why are there changes

Administered by the Central Provident Fund (CPF) Board, MediShield Life is a basic health insurance that protects all Singapore Citizens and Permanent Residents (PRs) against large medical bills and selected costly outpatient treatments. Designed to cover nine in ten subsidised bills at public healthcare institutions, this coverage has now dropped to cover just under eight in ten bills due to the rising medical costs. Changes thus aims to restore MediShield Life’s benefit back to covering nine in ten subsidised bills.


What are the changes

Changes will be implemented progressively from April 2025 onwards with some changes implemented in phases. Here are the key changes to your MediShield Life (MSHL).

1. Coverage limits

The revised MediShield Life will offer better coverage and fully cover nine in ten subsidised bills. For this, MediShield Life will increase claim limits for:

  • Annual policy claim limit – Increase from $150,000 to $200,000 per year.
  • Inpatient and day surgery claim limits – Intensive Care Unit Ward (ICU) limit will double and surgical procedure limits will also increase.
  • Outpatient claim limits – Increase in limits for benefits such as kidney dialysis and radiotherapy for cancer.
  • 2. Expanded coverage

    To address medical advancements and the shift in our healthcare needs:

  • Coverage for new medical technologies – For example, Cell, Tissue, and Gene Therapy Products (CTGTPs).
  • Home-Based Medical Care – To allow for more convenient care options to be covered.
  • High-Cost Treatments – Coverage for clinically effective and cost-effective treatments.
  • 3. Deductible and Co-insurance

    To moderate premium impact and keep larger bills affordable, new MSHL will implement:

  • Inpatient deductible – To increase by up to $1,500. This increase will be done in two phases.
  • Outpatient deductible – New outpatient deductible of $500 will be imposed.
  • Co-insurance – Reduced from a flat 10 per cent to a tiered structure of 3 to 10 per cent co-insurance to be consistent with how co-insurance is computed for inpatient bills.
  • Medisave withdrawal limits – Adjusted to allow individuals to use MediSave for co-insurance and revised deductible portion. Example below shows two scenarios with $0 cash outlay after the revised scheme.
  • 4. Premium adjustments

  • Increase in premiums – This increase will be done in phases starting from April 2025 and up to March 2028. Total premium increase is capped at 35 per cent, and works out to an average of 22 per cent increase per policyholder by the end of the third year. New premiums will take effect upon renewal.
  • Premium support measures – Government will provide premium support measures (i.e. offset package) and this will offset the cumulative increase in MSHL premiums over the next three years for almost all ages and income levels.

  • With the changes to MediShield Life, do I still need an Integrated Shield plan?

    The new MediShield Life is intended to fully cover nine in ten subsidised bills in public healthcare institutions. If you are comfortable with seeking treatment at Class B2/C wards in public hospitals, then MediShield Life should sufficiently address your needs.

    To recap, B2/C wards are naturally ventilated rooms with up to 6 beds in a ward. Rooms may not have attached bathrooms and televisions.


    If you are currently only on MediShield Life and would like higher coverage:

  • Standard Integrated Shield plan (B1 ward)
  • Designed as a no-frills product, benefits for standard IP plans are determined by the Government and are identical across all IP insurers. This offers a standardised affordable option for additional coverage beyond MediShield Life.

    While the standard B1 ward IP plan and the new MediShield Life plan both have an annual policy limit of $200,000, Standard IP offers higher coverage limits for both inpatient and outpatient treatments. Some of the difference in benefits can be found in the table below:


    Current MediShield Life

    New MediShield Life with effect from April 2025

    Standard Integrated Shield plan (B1 ward)

    Annual policy claim limit
    $150,000
    $200,000
    $200,000
    Co-insurance
    Flat 10%
    Tiered structure ranging from 3% to 10%
    10%
    Inpatient and day surgery limits
    Daily claim limit for first two days of normal ward stays
    $1,000
    $1,630
    $2,550
    Intensive Care Unit (ICU) ward limits
    $2,200 per day
    $5,140 per day
    $6,850 per day
    Psychiatric
    $160 per day, up to 60 days per policy year
    $230 per day, up to 60 days per policy year
    $680 per day, up to 60 days per policy year
    Community hospital: Rehabilitative Care
    $350 per day
    $370 per day
    $760 per day
    Surgical procedures
    $240 to $2,600 per procedure
    $240 to $3,900 per procedure
    $590 to $21,480 per procedure
    Outpatient claim limits
    Cancer drug treatment (for one primary cancer)
    $200 - $9,600 per month depending on treatment
    No change
    3x MSHL limit per month
    Cancer drug services (for one primary cancer)
    $3,600 per year
    No change
    2x MSHL limit per year
    Radiosurgery including Proton Beam Therapy - Category 4
    $10,000 per treatment course
    $15,700 per treatment course
    $31,300 per treatment course
    Kidney dialysis
    $1,100 per month
    $1,750 per month
    $3,740 per month

    Information in table is for illustration purposes only and are non-exhaustive. Please refer to the policy wording for more information. Information retrieved on 21 October 2024.

    Premiums for a Standard B1 ward IP plan:


    IncomeShield Standard Plan

    Singlife Shield Standard

    Raffles Shield Standard

    Age 20
    $36.00
    $46.86
    $39.73
    Age 30
    $45.00
    $50.94
    $48.90
    Age 40
    $67.00
    $71.31
    $63.15
    Age 50
    $140.00
    $137.53
    $127.33
    Age 60
    $176.00
    $169.10
    $166.05
    Age 65
    $242.00
    $292.36
    $280.14

    Premiums retrieved on 21 October 2024, and are for illustration purposes only.

    While Standard B1 ward plans are a step up from MediShield Life’s benefits, coverage from these plans are still not as comprehensive as Class A ward or private hospital IP plans. For example, Standard B1 IP plans do not provide as-charged coverage. Pre and post hospitalisation treatments are also not covered in Standard B1 IP plans.

    For Class B1 ward entitlements with as-charged coverage and higher benefits, consider Enhanced IncomeShield Basic, Singlife Shield Plan 3, or Raffles Shield B.

    (Read: A Guide to assessing your Enhanced IncomeShield plan)


    For private hospital treatments, or to further enhance your coverage:

    If you would like to get as charged coverage, opt for a Class A or Private hospital IP plan. Not only will this give you as charged coverage for inpatient and outpatient treatments, but you will also receive additional benefits such as coverage for pre and post hospitalisation treatments.

    With integrated shield plans, you will get:

  • Higher annual policy limits – Ranges from $200,000 to $2,000,000.
  • Different ward entitlements – Receive as charged coverage for class B1 or A ward in public hospitals, or at private hospitals.
  • Cancer treatment – Get up to 5x MSHL limit with Integrated Shield plans, and up to 23x MSHL limit with the addition of IP riders.
  • Pre and post hospitalisation treatment – Up to 180 days pre hospitalisation, and up to 365 days post hospitalisation coverage when you seek treatment at insurer’s preferred partners.

  • Have a question? Click the button below to speak to us:

    If you are unsure on which hospitalisation plan you need, or would like a second opinion for your policies.





    Available Products on FSMOne Insurance

    Term Life, Whole Life, Critical Illness, Annuity, Health, Endowment, General Insurance (Personal and Commercial)


    from AIG, Allianz, Cigna, Chubb, Etiqa Insurance, FWD Insurance, Great Eastern, Henner, Income, Manulife, MSIG, Raffles Health Insurance, Singlife, Sompo, Tokio Marine, and QBE.


    *Please check with our team if the product you want is available on FSMOne Insurance



    Read also,

  • Is private hospital insurance really necessary?
  • A Guide to assessing your Enhanced IncomeShield plan
  • PSA: Is the insurance policy your parents bought for you serving you well?
  • 1 in 5 Singaporeans lack life insurance coverage. Are you the 1 in 5?


  • Information obtained from:

    https://www.moh.gov.sg/news-highlights/details/government-accepts-medishield-life-council-s-recommendations-to-enhance-medishield-life-scheme---government-support-more-than-offsets-premium-increases

    https://www.straitstimes.com/singapore/health/medishield-life-to-offer-higher-claim-limits-better-coverage-premiums-to-rise-from-april-2025

    https://www.moh.gov.sg/healthcare-schemes-subsidies/medishield-life/medishield-life-faqs#sisp

    Information retrieved on 21 October 2024.



    Disclaimer:

    All materials and content found in this article are strictly for information purposes only and should not be considered as an offer or solicitation to transact in any product. This article is not a contract of insurance.

    Insurance products are underwritten by the respective insurance partners and distributed by iFAST Financial Pte Ltd (“iFAST”). You are advised to review the specific terms, conditions and exclusions in the relevant policy contract.

    You are advised to read the key product documents, including (but not limited to) the product summary, before deciding whether the product is suitable for you. You should consider carefully if the products you are purchasing are suitable for your financial objectives, experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of a product, please seek advice from a financial adviser before making a decision to purchase the product.

    While iFAST and its third-party providers strive to provide accurate and timely information, there may be inadvertent omissions, inaccuracies, and typographical errors. Opinions expressed herein are subjected to change without notice.

    Purchasing a life insurance policy is a long-term commitment, and early termination may involve significant costs. The surrender value, if any, may be zero or less than the total premiums paid.

    This advertisement has not been reviewed by the Monetary Authority of Singapore.

    All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

    Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

    iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.